Company to Hold Conference Call at 4:30 p.m. EDT Today
SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
reported financial results for the second quarter ended June 30, 2014.
Loss from operations decreased to $7.8 million for the three months
ended June 30, 2014 compared with $18.0 million for the comparable
period in 2013, and decreased to $15.0 million for the six months ended
June 30, 2014 compared with $26.0 million for the comparable period in
2013. The decrease in loss from operations for the three and six month
periods ended June 30, 2014 compared to the prior year periods was due
to lower research and development expenses primarily attributable to a
$10.0 million upfront payment to Array BioPharma Inc. (Array) in June
2013. The decrease was partly offset by a slight increase in general
and administrative expenses.
Net loss for the three months ended June 30, 2014 was $6.0 million, or
$0.09 per basic and diluted share, compared with a net loss of $16.4
million, or $0.28 per basic and diluted share, for the comparable
period in 2013. Net loss for the six months ended June 30, 2014 was
$15.6 million, or $0.22 per basic and diluted share, compared with a
net loss of $24.7 million, or $0.43 per basic and diluted share, for
the comparable period in 2013. The decrease in net loss for the three
months ended June 30, 2014 compared to the prior year period was due to
lower research and development expenses primarily attributable to an
upfront payment of $10.0 million to Array in June 2013, partially
offset by a slight increase in general and administrative expenses. The
decrease in net loss for the six months ended June 30, 2014 compared to
the prior year period was due to lower research and development
expenses primarily attributable to the upfront payment of $10.0 million
to Array in June 2013, partially offset by $0.7 million of non-cash
expense from the change in fair value of warrant liability for the six
months ended June 30, 2014 compared to $1.3 million of non-cash income
from the change in fair value of warrant liability for the six months
ended June 30, 2013, and a slight increase in general and
administrative expenses.
As of June 30, 2014, Oncothyreon's cash, cash equivalents and
investments were $58.5 million, compared to $72.6 million at December
31, 2013, a decrease of $14.1 million, or 19.4 percent. The decrease
was primarily attributable to $13.7 million of cash used in operations
during the six months ended June 30, 2014.
Financial Guidance
Oncothyreon believes the following financial guidance to be correct as
of the date provided. Oncothyreon is providing this guidance as a
convenience to investors and assumes no obligation to update it.
Oncothyreon currently expects operating expenses in 2014 to be lower
than in 2013, which included the one-time upfront payment to Array.
Oncothyreon currently expects cash used in operations in 2014 to be
approximately $30 to $33 million, including expenses associated with
the acquisition of Alpine Biosciences, Inc. This guidance remains
unchanged from that given in the prior quarter. As a result,
Oncothyreon estimates that its existing cash, cash equivalents and
investments will be sufficient to fund operations for at least the next
12 months.
Conference Call and Webcast
Oncothyreon will conduct a conference call today, August 11, 2014 at
4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its second
quarter 2014 financial results and provide a review of its pipeline of
products in development. To participate in the call by telephone,
please dial (877) 280-7291 (United States) or (707) 287-9361
(International). In addition, the call will be webcast live and can be
accessed on the "Events" page of the "News & Events" section of
Oncothyreon's website at www.oncothyreon.com. An archive of the webcast will be available after completion of the
discussion and will be posted on Oncothyreon's website.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
Forward-Looking Statements
In order to provide Oncothyreon's investors with an understanding of its
current results and future prospects, this release contains statements
that are forward-looking. Any statements contained in this press
release that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as "believes," "anticipates,"
"plans," "expects," "will," "intends," "potential," "possible" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements include Oncothyreon's
expectations regarding future expenses and the use and adequacy of cash
resources.
Forward-looking statements involve risks and uncertainties related to
Oncothyreon's business and the general economic environment, many of
which are beyond its control. These risks, uncertainties and other
factors could cause Oncothyreon's actual results to differ materially
from those projected in forward-looking statements, including the risks
associated with the costs and expenses of developing its product
candidates, the adequacy of financing and cash, cash equivalents and
investments, changes in general accounting policies, general economic
factors, achievement of the results it anticipates from its clinical
trials of its product candidates and its ability to adequately obtain
and protect its intellectual property rights. Although Oncothyreon
believes that the forward-looking statements contained herein are
reasonable, it can give no assurance that its expectations are correct.
All forward-looking statements are expressly qualified in their
entirety by this cautionary statement. For a detailed description of
Oncothyreon's risks and uncertainties, you are encouraged to review the
documents filed with the securities regulators in the United States on
EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any
obligation to publicly update its forward-looking statements based on
events or circumstances after the date hereof.
Additional Information
Additional information relating to Oncothyreon can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
ONCOTHYREON INC. 2601 Fourth Avenue, Suite 500, Seattle, WA 98121
Tel: (206) 801-2100 Fax: (206) 801-2101
http://www.oncothyreon.com
|
ONCOTHYREON INC.
|
|
Condensed Consolidated Statements of Operations
|
|
(In thousands except share and per share amounts)
|
|
(Unaudited)
|
|
|
Three months ended
|
|
Six months ended
|
|
June 30,
|
|
June 30,
|
|
|
2014
|
|
2013
|
|
2014
|
|
|
2013
|
|
|
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
$
|
5,400
|
|
$
|
16,058
|
|
$
|
10,213
|
|
$
|
21,857
|
|
General and administrative
|
|
2,397
|
|
|
1,989
|
|
|
4,744
|
|
|
4,181
|
|
Total operating expenses
|
|
7,797
|
|
|
18,047
|
|
|
14,957
|
|
|
26,038
|
|
Loss from operations
|
|
(7,797)
|
|
|
(18,047)
|
|
|
(14,957)
|
|
|
(26,038)
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment and other income (expense), net
|
|
20
|
|
|
24
|
|
|
41
|
|
|
52
|
|
Change in fair value of warrant liability
|
|
1,745
|
|
|
1,625
|
|
|
(732)
|
|
|
1,300
|
|
Total other income (expense), net
|
|
1,765
|
|
|
1,649
|
|
|
(691)
|
|
|
1,352
|
|
Net loss
|
$
|
(6,032)
|
|
$
|
(16,398)
|
|
$
|
(15,648)
|
|
$
|
(24,686)
|
|
Net loss per share - basic and diluted
|
$
|
(0.09)
|
|
$
|
(0.28)
|
|
$
|
(0.22)
|
|
$
|
(0.43)
|
|
Shares used to compute basic and diluted net loss per share
|
|
70,762,031
|
|
|
58,710,574
|
|
|
70,725,341
|
|
|
57,967,534
|
|
ONCOTHYREON INC.
|
|
Consolidated Balance Sheet Data
|
|
(In thousands except share amounts)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
|
|
June 30, 2014
|
|
December 31, 2013
|
|
|
Cash, cash equivalents and investments
|
|
$
|
58,479
|
|
|
$
|
72,562
|
|
|
Total assets
|
|
$
|
63,574
|
|
|
$
|
77,746
|
|
|
Long term liabilities
|
|
$
|
2,395
|
|
|
$
|
1,536
|
|
|
Stockholders' equity
|
|
$
|
57,252
|
|
|
$
|
71,550
|
|
|
Common shares outstanding
|
|
|
70,810,631
|
|
|
|
70,673,143
|
SOURCE Oncothyreon Inc.